TABLE 1.
Surface expression of CD4, CD8, CCR5, and CXCR4 4 days after the addition of MV (MOI of 0.15) to HIV-1-infected PBMCsa
| HIV-1 strain | MV or control | % CD4+ | % CD8+ | % CCR5+ | % CXCR4+ |
|---|---|---|---|---|---|
| HIV-1BaL | None | 51.5 ± 2.9 | 29.8 ± 3.3 | 4.1 ± 2.6 | ND |
| Chicago-1 MV | 54.0 ± 3.3 | 28.9 ± 3.8 | 4.1 ± 2.9 | ND | |
| Edmonston MV | 53.7 ± 2.7 | 28.2 ± 3.6 | 6.1 ± 3.3 | ND | |
| Vero cell lysate | 50.7 ± 3.3 | 28.8 ± 3.3 | 3.4 ± 2.2 | ND | |
| HIV-1IIIB | None | 49.3 ± 3.3 | 34.2 ± 5.8 | NDb | 57.9 ± 3.8 |
| Chicago-1 MV | 48.0 ± 3.3 | 35.8 ± 3.6 | ND | 77.9 ± 3.2c | |
| Edmonston MV | 50.5 ± 2.6 | 37.3 ± 5.0 | ND | 64.1 ± 6.3 | |
| Vero cell lysate | 49.6 ± 3.7 | 33.3 ± 5.7 | ND | 63.1 ± 2.6 |
a
Vero cell lysate (1:10) was used as control. Data represent the means ± standard errors of the means of the percentage of positive cells from five to nine experiments.
b
ND, not determined.
c
P < 0.05 compared to Vero cell lysate.